Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1)

Bibliography

• Barrow WW. Treatment of mycobacterial infections. Rev Sci Tech Off Int Epiz 2001;20(1):55-70
   PubMed Web of Science ®Google Scholar
• Niemann S, Richter E, Rüsch-Gerdes S. Differentiation among members of the mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of M. bovis. J Clin Microbiol 2000;38(1):152-7
   PubMed Web of Science ®Google Scholar
• Richter E, Weizenegger M, Rüsch-Gerdes S, et al. Evaluation of genotype MTBC assay for differentiation of clinical mycobacterium tuberculosis complex isolates. J Clin Microbiol 2003;41(6):2672-5
   PubMed Web of Science ®Google Scholar
• Pinheiro RO, de Souza Salles J, Sarno EN, et al. Mycobacterium leprae–host-cell interactions and genetic determinants in leprosy: an overview. Future Microbiol 2011;6(2):217-30
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367-416
   PubMed Web of Science ®Google Scholar
• WHO. Global tuberculosis control: WHO report 2014. World Health Organization; Geneva, Switzerland: 2014
   Google Scholar
• Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001;1(1):20-30
   PubMed Web of Science ®Google Scholar
• WHO. World health organization global tuberculosis programme - report on the tuberculosis epidemic world health organization. World Health Organization, Geneva, Switzerland: 1997
   Google Scholar
• Venkataswamy MM, Goldberg MF, Baena A, et al. In vitro culture medium influences the vaccine efficacy of mycobacterium bovis BCG. Vaccine 2012;30(6):1038-49
   PubMed Web of Science ®Google Scholar
• WHO. “Tuberculosis.” WHO factsheet (revised). No. 104 World Health Organization; Geneva, Switzerland: 1996
   Google Scholar
• Raviglione MC, Uplekar MW. WHO’s new stop TB strategy. Lancet 2006;367(9514):952-5
   PubMed Web of Science ®Google Scholar
• Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator mycobacterium tuberculosis. Nat Rev Microbiol 2008;6(1):41-52
   PubMed Web of Science ®Google Scholar
• Marigot-Outtandy D, Perronne C. Les nouveaux antituberculeux. Réanimation 2009;18(4):334-42
   Google Scholar
• Dye C, Garnett GP, Sleeman K, et al. Prospects for worldwide tuberculosis control under the WHO DOTS Strategy. Lancet 1998;352(9144):1886-91
   PubMed Web of Science ®Google Scholar
• Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42(1):156-68
   PubMed Web of Science ®Google Scholar
• Cohen T, Jenkins HE, Lu C, et al. On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resist Update 2014;17(4):105-23
   PubMed Web of Science ®Google Scholar
• Stewart GR, Robertson BD, Young DB. Tuberculosis: a problem with persistence. Nat Rev Microbiol 2003;1(2):97-105
   PubMed Web of Science ®Google Scholar
• WHO. Definitions and reporting framework for tuberculosis – 2013 revision. World Health Organization; Geneva, Switzerland: 2013
   Google Scholar
• Furin J. The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007;13(3):212-17
   PubMed Web of Science ®Google Scholar
• Dooley KE, Obuku EA, Durakovic N, et al. World health organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013;207(9):1352-8
   PubMed Web of Science ®Google Scholar
• Quémard A, Lanéelle G, Lacave C. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob Agents Chemother 1992;36(6):1316-21
   PubMed Web of Science ®Google Scholar
• Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002;277(15):12824-9
   PubMed Web of Science ®Google Scholar
• Ang ML, Siti ZZ, Shui G, et al. An ethA-ethR-deficient mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition. Infect Immun 2014;82(5):1850-9
   PubMed Web of Science ®Google Scholar
• DeBarber AE, Mdluli K, Bosman M, et al. Ethionamide activation and sensitivity in multidrug-resistant mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000;97(17):9677-82
   PubMed Web of Science ®Google Scholar
• Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 2000;275(36):28326-31
   PubMed Web of Science ®Google Scholar
• Morlock GP, Metchock B, Sikes D, et al. EthA, InhA, and KatG loci of ethionamide-resistant clinical mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003;47(12):3799-805
   PubMed Web of Science ®Google Scholar
• Lo MC, Aulabaugh A, Jin G, et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 2004;332(1):153-9
   PubMed Web of Science ®Google Scholar
• Flipo M, Willand N, Lecat-Guillet N, et al. Discovery of novel N-phenylphenoxyacetamide derivatives as ethr inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. J Med Chem 2012;55(14):6391-402
   PubMed Web of Science ®Google Scholar
• Crauste C, Willand N, Villemagne B, et al. Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands. Anal Biochem 2014;452:54-66
   PubMed Web of Science ®Google Scholar
• Willand N, Dirie B, Carette X, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009;15(5):537-44
   PubMed Web of Science ®Google Scholar
• Flipo M, Desroses M, Lecat-Guillet N, et al. Ethionamide boosters. 2. combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. J Med Chem 2011;55(1):68-83
   PubMed Web of Science ®Google Scholar
• Deprez B, Willand N, Flipo M, et al. Compounds having an EthR inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds. WO060744; 2013
   Google Scholar
• Willand N, Deprez B, Baulard A, et al. Spiroisoxazoline compounds having an activity potentiating the activity of an antibiotic. WO096369; 2014
   Google Scholar
• Willand N, Deprez B, Baulard A, et al. Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria. WO096378; 2014
   Google Scholar
• Villemagne B, Flipo M, Blondiaux N, et al. Ligand efficiency driven design of new inhibitors of mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J Med Chem 2014;57(11):4876-88
   PubMed Web of Science ®Google Scholar
• Surade S, Ty N, Hengrung N, et al. A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochem J 2014;458(2):387-94
   PubMed Web of Science ®Google Scholar
• Schoenmakers R, Weber W, Gitzinger M, et al. Composition for treatment of tuberculosis. United States. US0101080; 2012
   Google Scholar
• Dillon NA, Peterson ND, Rosen BC, et al. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide. Antimicrob Agents Chemother 2014;58(12):7258-63
   PubMed Web of Science ®Google Scholar